Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.44 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arq-621 SCHEMBL29479147 | 1.00 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| Arq-621 SCHEMBL2399429 | 1.00 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| Arq-621 SCHEMBL30136957 | 1.00 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL2399499 | 0.96 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL361542 | 0.96 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL361313 | 0.93 | KIF11 (0.45) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL2399397 | 0.92 | KIF11 (0.38) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL2396860 | 0.92 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL362139 | 0.92 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL2398230 | 0.92 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582682-B1 | MITOTIC KINESIN INHIBITORS FOR USE IN THE TREATMETNOF PULMONARY ARTERIAL HYPERTENSION | CYTOKINETICS INC (US) | 2015-01-14 | — | — | EP | claimed |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. | 2013-08-15 | — | — | US | claimed |
| EP-2582682-A1 | METHODS OF TREATING LUNG DISEASE | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| EP-2173724-B1 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE INC (US) | 2012-12-05 | — | — | EP | claimed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | claimed |
| WO-2012009097-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | claimed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-12-19 | — | — | US | disclosed |
| CN-117651700-A | 2-aminobenzothiazole compounds and methods of use | 安进公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117561063-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-2582682-B1 | MITOTIC KINESIN INHIBITORS FOR USE IN THE TREATMETNOF PULMONARY ARTERIAL HYPERTENSION | CYTOKINETICS INC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. | 2013-08-15 | — | — | US | disclosed |
| EP-2173724-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009002808-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002808-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | KIF11 2462/4885MAP1LC3B 574/4885CYP3A4 568/4885 |
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | KIF11 1883/4885MAP1LC3B 3565/4885CYP3A4 2069/4885 |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | KIF11 2462/4885MAP1LC3B 574/4885CYP3A4 568/4885 |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | KIF11 1492/4885MAP1LC3B 2066/4885CYP3A4 2895/4885 |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | KIF5B, KIF2C, KIF18B | KIF11 12/4885MAP1LC3B 106/4885CYP3A4 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.